IVACC — Intervacc AB Share News
0.000.00%
Last trade - 00:00- SEK443.06m
- SEK297.43m
- SEK20.09m
Brief: Intervacc Q1 Operating Loss Widens To SEK 10.7 Mln
Brief: Intervacc AB Says First Batch Of Strangvac, A Vaccine Against Equine Strangles, Has Been Released For Sale In Sweden
Brief: Ema Extends Shelf Life Of Antigens Used In Strangvac
Brief: Intervacc Q4 Operating Loss Widens To SEK 8.8 Million
Brief: Intervacc Applies For Permit For Sale Of Strangvac In US
Brief: Intervacc Comments On The Trading Halt Of The Company's Share On Nasdaq First North
Brief: Sales Of Intervacc's Strangles Vaccine To Begin In Q1 2022
Brief: Intervacc Q3 Operating Loss At SEK 8.3 Million
Brief: Intervacc Says U.S. Patent Approval For Co's Vaccine Against Infections Caused By Streptococcus Suis
Brief: Intervacc Q2 Oper Loss Widens To SEK 6.1 Mln
Brief: Intervacc Says Norwegian Medicines Agency Granted Marketing Authorisation For Strangvac
Brief: Intervacc Says Receives Confirmation Of Positive Outcome For Strangvac From VMD In UK
Brief: Intervacc AB Receives Positive CVMP Opinion For Strangvac, A Vaccine Against Equine Strangles, In EU
Brief: Intervacc, The Karolinska Institutet Sign Contract For Animal Health Vaccines
Brief: Intervacc Q1 Operating Loss Widens To SEK 6.5 Million
Brief: Intervacc AB And Dechra Pharmaceuticals Enter Into An Agreement To Commercialize Strangvac In Europe
Brief: Intervacc Q4 Operating Loss Narrows To SEK 7.2 Million
Brief: Intervacc Q3 Operating Loss Widens To SEK 6.4 Million
Brief: Intervacc Q2 Operating Loss Narrows To Sek 5.8 Million